Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Results available

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

ClinicalTrials.gov ID: NCT02808650

Public ClinicalTrials.gov record NCT02808650. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1 inhibitor LY2606368 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study identification

NCT ID
NCT02808650
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Children's Oncology Group
Network
Enrollment
30 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Months to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 27, 2017 (Actual)
Primary completion
Dec 31, 2019 (Actual)
Completion
Mar 31, 2021 (Actual)
Last update posted
Dec 20, 2023

2017 – 2021

United States locations

U.S. sites
21
U.S. states
18
U.S. cities
21
Facility City State ZIP Site status
Children's Hospital of Alabama Birmingham Alabama 35233 —
Phoenix Childrens Hospital Phoenix Arizona 85016 —
Children's Hospital Los Angeles Los Angeles California 90027 —
Children's Hospital of Orange County Orange California 92868 —
UCSF Medical Center-Mission Bay San Francisco California 94158 —
Children's Hospital Colorado Aurora Colorado 80045 —
Children's National Medical Center Washington D.C. District of Columbia 20010 —
Children's Healthcare of Atlanta - Egleston Atlanta Georgia 30322 —
Lurie Children's Hospital-Chicago Chicago Illinois 60611 —
Riley Hospital for Children Indianapolis Indiana 46202 —
Dana-Farber Cancer Institute Boston Massachusetts 02215 —
C S Mott Children's Hospital Ann Arbor Michigan 48109 —
University of Minnesota/Masonic Cancer Center Minneapolis Minnesota 55455 —
Washington University School of Medicine St Louis Missouri 63110 —
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032 —
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229 —
Children's Hospital of Philadelphia Philadelphia Pennsylvania 19104 —
Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania 15224 —
Saint Jude Children's Research Hospital Memphis Tennessee 38105 —
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center Houston Texas 77030 —
Seattle Children's Hospital Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02808650, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2023 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02808650 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →